Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 261 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Glioblastoma Multiforme of the Brain Clear all

Conditions: Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Gliosarcoma
Interventions: Adavosertib, Laboratory Biomarker Analysis, Pharmacological Study, Radiation Therapy; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 37 Months to 21 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more

Conditions: Adult Brain Glioblastoma, Recurrent Adult Brain Neoplasm
Interventions: Electric Field Therapy, Bevacizumab, Carmustine, Quality-of-Life Assessment; Procedure · Biological · Drug + 1 more
Lead sponsor: University of California, Davis; Other
Eligibility: 22 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Sacramento, California • Atlanta, Georgia

Conditions: Glioblastoma, Gliosarcoma
Interventions: Imatinib Mesylate & Hydroxyurea; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
Interventions: Sutent (sunitinib); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glioblastoma
Interventions: Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells; Biological
Lead sponsor: In8bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Louisville, Kentucky + 2 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Temodar and O6-Benzylguanine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cancer
Interventions: cyproheptadine hydrochloride, placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 2 Years to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 14
States / cities: Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more

Conditions: Glioblastoma
Interventions: MRI-guided Laser Heat Ablation (MLA), Doxorubicin, Blood draw - dendritic cells, Dynamic Susceptibility Contrast Magnetic Resonance Imaging; Device · Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Brain and Central Nervous System Tumors
Interventions: gefitinib, temozolomide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more

Conditions: Adult Brain Glioblastoma
Interventions: Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Glioma, Glioblastoma
Interventions: Focused ultrasound (FUS); Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Charlottesville, Virginia + 1 more

Conditions: Brain and Central Nervous System Tumors
Interventions: radiation therapy, Celecoxib; Radiation · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 4 more

Conditions: Brain and Central Nervous System Tumors
Interventions: conventional surgery, iodine I 131 monoclonal antibody 81C6, radiation therapy; Procedure · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: GBM, Glioblastoma Multiforme
Interventions: DCVax-L; Biological
Lead sponsor: Northwest Biotherapeutics; Industry
Eligibility: 18 Years to 70 Years
U.S. locations: 27
States / cities: Little Rock, Arkansas • Los Angeles, California • Newport Beach, California + 23 more

Conditions: Grade IV Glioma, Grade IV Astrocytoma, Glioblastoma Multiforme
Interventions: TVI-Brain-1; Biological
Lead sponsor: TVAX Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: Kansas City, Missouri • St Louis, Missouri • Dallas, Texas + 1 more

Conditions: High Grade Glioma
Interventions: 5 Aminolevulinic Acid, CV01-delivered ultrasound; Drug · Device
Lead sponsor: Alpheus Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: St Louis, Missouri • Amherst, New York • Lake Success, New York

Conditions: Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, GBM, Brain Cancer, High Grade Glioma
Interventions: Laparoscopically harvested omental tissue autograft; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme
Interventions: CT-322, irinotecan hydrochloride; Drug
Lead sponsor: Adnexus, A Bristol-Myers Squibb R&D Company; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 10
States / cities: La Jolla, California • Lexington, Kentucky • Boston, Massachusetts + 7 more

Conditions: Glioblastoma Multiforme of the Brain
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioblastoma Multiforme
Interventions: CT-322, Temozolomide, Radiation Therapy; Drug · Procedure
Lead sponsor: Adnexus, A Bristol-Myers Squibb R&D Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more

Conditions: Glioblastoma, Astrocytoma, Pineoblastoma, Rhabdoid Tumor, Supratentorial Neoplasms
Interventions: Stem Cell Transplant; Procedure
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 18 Months to 25 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Low Grade Glioma of Brain, Glioblastoma, Metastasis to Brain
Interventions: LUM Imaging System; Combination Product
Lead sponsor: Lumicell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioma
Interventions: 5-Aminolevuline Acid; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Adult Brain Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
Interventions: Dimethyl Fumarate, Temozolomide, Radiation Therapy; Drug · Radiation
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Search by objective public record fields.

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

Sunitinib to Treat Recurrent Brain Cancer

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption

Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors

Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors

Feasibility of the LUM Imaging System for Detection of Cancer to the Brain

A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme